Biography:Jane Grogan

From HandWiki
Jane L. Grogan
CitizenshipAustralia
Education
Scientific career
Fields
InstitutionsBiogen, Genentech, ArsenalBio, Graphite Bio

Jane L. Grogan is an Australian-born, US-based scientist specializing in immunology and cancer research. In 2009, she was the corresponding author of the paper that first described a novel inhibitory immune receptor that became a drug target in cancer immunotherapy.[1][2] Grogan is currently the executive vice president and head of research at Biogen.[3][4]

Education

Grogan completed her undergraduate degree in biochemistry and pharmacology at the University of Melbourne, Australia and a PhD in Immunology at Leiden University in the Netherlands.[3][4] Her post-doctoral training was at the German Rheumatism Research Centre Berlin (DRFZ) in Berlin as an Alexander von Humboldt Fellow.[3] She then moved to the United States to take up a position as a Howard Hughes Fellow at the University of California, San Francisco.[3]

Career

Grogan joined Genentech in 2004 and spent the next fifteen years there. Her positions included principal scientist in cancer immunology and head of adaptive tumor immunity.[3][5] She founded and was the original host of the science journalism podcast produced by Genentech called Two Scientists Walk Into a Bar.[6][7]

In 2019, she became the founding chief scientific officer of ArsenalBio, a cell-therapy startup.[8] She then served as the chief scientific officer of Graphite Bio.[3] Between these positions, she advised biotechnology companies and sat on the scientific advisory board of Bicycle Therapeutics.[9] Since 2021, she has been on the board of the Federation of Clinical Immunology Societies.[9]

Grogan was appointed as executive vice president and head of research at Biogen in September 2023.[5][10][11]

Research

Grogan's initial research focused on mechanisms of T cell activation, tolerance-induction and epigenetic modifiers. In 2009, Grogan and her lab at Genentech described TIGIT, an inhibitory receptor on lymphocytes that suppresses T cell activation.[1]

She has published more than 60 papers and is an inventor on more than 20 patents.[3]

Select publications

References

  1. ↑ 1.0 1.1 Yu, Xin; Harden, Kristin; C Gonzalez, Lino; Francesco, Michelle; Chiang, Eugene; Irving, Bryan; Tom, Irene; Ivelja, Sinisa et al. (January 2009). "The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells" (in en). Nature Immunology 10 (1): 48–57. doi:10.1038/ni.1674. ISSN 1529-2908. PMID 19011627. http://www.nature.com/articles/ni.1674. 
  2. ↑ Harjunpää, H.; Guillerey, C. (May 2020). "TIGIT as an emerging immune checkpoint". Clinical and Experimental Immunology 200 (2): 108–119. doi:10.1111/cei.13407. PMID 31828774. PMC 7160651. https://pubmed.ncbi.nlm.nih.gov/31828774/. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "Biogen Appoints Jane Grogan as Head of Research". Biogen. 6 September 2023. https://investors.biogen.com/news-releases/news-release-details/biogen-appoints-jane-grogan-head-research. Retrieved 9 August 2024. 
  4. ↑ 4.0 4.1 "Jane Grogan, Ph. D.". Biogen. 2026-09-17. https://www.biogen.com/company/leadership/grogan-jane.html. Retrieved 9 August 2024. 
  5. ↑ 5.0 5.1 Bell, Jacob (6 September 2023). "Biogen, continuing executive revamp, finds a new research head" (in en-US). https://www.biopharmadive.com/news/biogen-research-head-jane-grogan-appointment/692833/. 
  6. ↑ Bulik, Beth Snyder (26 October 2016). "Genentech’s podcasting debut taps science podcast geek chic | Fierce Pharma" (in en). www.fiercepharma.com. https://www.fiercepharma.com/marketing/genetech-s-podcasting-debut-two-scientists-walk-into-a-bar-taps-science-podcast-geek-chic. 
  7. ↑ "Genentech: Topics | Two Scientists Walk Into A Bar" (in en-US). 2026-09-18. https://www.gene.com/topics/two-scientists-walk-into-a-bar. 
  8. ↑ "ArsenalBio emerges from stealth with $85 million and a dream team to fight cancer" (in en-US). https://techcrunch.com/2019/10/17/arsenalbio-emerges-from-stealth-with-85-million-and-a-dream-team-to-fight-cancer/. 
  9. ↑ 9.0 9.1 Bushak, Lecia (September 6, 2023). "Biogen hires Jane Grogan as head of research". https://www.mmm-online.com/home/channel/people-moves/biogen-hires-jane-grogan-as-head-of-research/. 
  10. ↑ Bayer, Max (October 10, 2023). "New Biogen research chief Jane Grogan looks to apply biotechs' scrappiness to a pharma in flux". https://www.fiercebiotech.com/biotech/new-biogen-research-chief-grogan-looks-apply-biotechs-scrappiness-pharma-flux. 
  11. ↑ Mullard, Asher (November 8, 2023). "Immunology on the brain" (in en-US). Nature Reviews Drug Discovery. doi:10.1038/d41573-023-00183-w. https://www.nature.com/articles/d41573-023-00183-w. Retrieved 2026-09-18.